hotspot -WSS

hotspot

author：comprehensive 2025-10-01 20:16:44 - browse：31759

illustration of one blue dna strand — Adobe

The Food and Drug Administration is convening a meeting of outside experts on Tuesday to review exa-cel, a CRISPR-based treatment for sickle cell disease made by Vertex Pharmaceuticals and CRISPR Therapeutics.

Tuesday’s meeting is set up a bit differently than most FDA advisory panels. The agency has not raised any concerns about exa-cel’s efficacy or safety, and there will not be a typical vote at the end of the day on whether the data from exa-cel’s pivotal clinical trial support an approval as a treatment for sickle cell disease.

Instead, the FDA is seeking input about the methods used by Vertex and CRISPR Therapeutics to evaluate the risk of inadvertently making unwanted changes to patients’ DNA — so-called off-target editing — when exa-cel is administered.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Does aspartame cause cancer? What new WHO guidance says

explore

WSS

Study on Amgen’s bispecific immunotherapy produces positive data

Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

Global childhood vaccinations edge closer to pre

Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

Results on Novartis prostate cancer therapy could expand its use

Does aspartame cause cancer? What new WHO guidance says

leisure time

hotspot

explore

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

STAT Readout: Friday, Oct. 20 biotech updates

Continuity nursing helped my family in our darkest PICU moments

Roivant's CEO is a star, but biotech's black hole persists

Tori Bowie and the unacceptable rates of Black maternal death

STAT Summit: How researchers deal with rejection

Hollywood unions extend contract negotiations for actors

Roivant's CEO is a star, but biotech's black hole persists

Medicare details structure of new drug price negotiation program

CZI to create biohub to build anti

entertainment

UnitedHealth, Optum discontinue NaviHealth name

Global childhood vaccinations edge closer to pre

J&J expands global access to TB drug amid advocacy campaign

Michigan AG announces felony charges against 'fake electors' in 2020 election plot

Blood tests recalled over risk of missed heart attack diagnosis

Does aspartame cause cancer? What new WHO guidance says

hotspot

explore

knowledge

explore